Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| So, you're talking about millions of patients who -- if the efficacy proves out, which, again, another readout over the weekend suggests that we're very happy with some of the efficacy rates we're seeing will be -- could be a major player within the IBD psoriasis space |
| Tim Schmidt and his leadership team are doing a fantastic job getting after that |
| So right now, I'd say, David, we're probably pretty good at harnessing the efficiencies that AI can deliver |
| how to operate much more efficiently and differently, which has enabled you to also put forward plans to continue to drive margin strength despite aggressive reinvestment in the business |
| And that's where we've been able to create some great value for shareholders |
| So, we're very proud of what the team was able to accomplish |
| So, I think that it's very bright |
| The Company's balance sheet is really in an exceptional position |
| So that positions us very well to broaden out the Interventional Solutions portfolio |
| Like I said earlier, we're really thrilled with the Abiomed acquisition |
| So, it's a great position to be in |
| And the acceleration serves our business well |
| So, we think we're very well positioned |
| The team did a fantastic job without a playbook, right, pushing ahead, getting the right people to make the decision and then course-correcting when something went wrong |
| There is an opportunity to improve our margins in MedTech |
| And I was interested in -- obviously, J&J is a strong and very powerful company with a lot of levers |
| I think that sets us up very well for what we see in terms of acceleration of where we go tomorrow |
| So, we're very well positioned |
| And I think the last couple of years have, quite frankly, formed us to be a much better organization for what are seemingly faster times |
| Much -- just like I said in my first response: having that innovation that elevates the current standard of care puts you in a very good position to have negotiations with some of the payers |
| So we think we're very well positioned to meet the margin commitments going forward |
| So, our margin profile remains very much intact despite what might have been a noisy fourth quarter because of that IPR&D charge |
| We feel pretty good |
| I think about JNJ-2113, so our targeted oral peptide, that provides tremendous opportunity in some of the spaces that we play today, specifically psoriasis and IBD |
| And we have good relationships with those payers |
| So, we're very excited about what lays ahead for Johnson & Johnson |
| So, the pharm team, I think, takes great pride in maybe not having a headline at the time the deal is signed, but having a headline when the product is about to be launched |
| The good news is Johnson & Johnson has been at this a while, has been competitive for a while |
| TECVAYLI is off to a very strong start |
| I think nipocalimab is another big one that we're excited about |
| Statement |
|---|
| But I think there were some initial margin concerns |
| This is a problem for Johnson & Johnson, certainly, but it's also a problem, I think, for industry and American business at large |
| We did have some headwinds in terms of margin |
| We thought that would be disconcerning on a number of fronts, not just for our company but for the industry at large |
| In Pharmaceuticals, I think there was a slide that we put up that identified about six products that we thought The Street was severely underestimating by different degrees |
| But we also -- again, we're not oblivious to the fact that it is providing an overhang now |
| And so, in terms of I&I and formulary placement, clearly, AbbVie has been dominant and constrained the growth, obviously, of TREMFYA |
| David Risinger Most would just blame the sell-side |
| So, we're not oblivious to the fact that, that does provide an overhang |
| Now I do think those turbulent times has accelerated things |
| Yes, I'm sure very difficult for you to balance given that no one knows what causes cancer |
| We've lost on price almost each of those years by an average of, let's call it, 3% to 5% |
| The complexity of human biology and disease and the actual appropriate inputs and whether you have enough of them with the right data sets makes it very tough |
| Just when you reported the fourth quarter, there was some noise from medical device analysts |
| So, in candor, I didn't do a good job of explaining that very well during the fourth quarter |
| So, I'm sure it's difficult to part with any money at all |
| I think shedding some light on just the questionable data that expert witnesses for the other side puts up will be illuminating |
| I would say I've been fortunate |
Please consider a small donation if you think this website provides you with relevant information